Sigurdur Ingvarsson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9156365/publications.pdf

Version: 2024-02-01

		186265	168389
78	2,988	28	53
papers	citations	h-index	g-index
80	80	80	3321
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 1571-1575.	7.1	301
2	Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Research, 1997, 57, 1222-7.	0.9	275
3	High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Research, 1996, 56, 3663-5.	0.9	157
4	Loss of heterozygosity at chromosome 1p in different solid human tumours: association with survival. British Journal of Cancer, 1999, 79, 1468-1474.	6.4	150
5	Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13. Cancer Research, 1995, 55, 4830-2.	0.9	128
6	Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. Oncogene, 2005, 24, 4540-4548.	5.9	111
7	Chromosome alterations and E-cadherin gene mutations in human lobular breast cancer. British Journal of Cancer, 1999, 81, 1103-1110.	6.4	97
8	Altered expression of E-cadherin in breast cancer. European Journal of Cancer, 2000, 36, 1098-1106.	2.8	90
9	Molecular genetics of breast cancer progression. Seminars in Cancer Biology, 1999, 9, 277-288.	9.6	85
10	Chromosomal assignment of retinoic acid receptor (RAR) genes in the human, mouse, and rat genomes. Genomics, 1991, 10, 1061-1069.	2.9	84
11	Loss of heterozygosity at chromosome 11 in breast cancer: association of prognostic factors with genetic alterations. British Journal of Cancer, 1995, 72, 696-701.	6.4	84
12	Mapping loss of heterozygosity at chromosome 13q: loss at 13q12-q13 is associated with breast tumour progression and poor prognosis. European Journal of Cancer, 1998, 34, 2076-2081.	2.8	83
13	The LIMD1 protein bridges an association between the prolyl hydroxylases and VHL to repress HIF-1 activity. Nature Cell Biology, 2012, 14, 201-208.	10.3	77
14	Structure and expression of B-myc, a new member of the myc gene family Molecular and Cellular Biology, 1988, 8, 3168-3174.	2.3	63
15	Alterations of E-cadherin and \hat{I}^2 -catenin in gastric cancer. BMC Cancer, 2001, 1, 16.	2.6	53
16	High frequency of LOH, MSI and abnormal expression of FHIT in gastric cancer. European Journal of Cancer, 2002, 38, 728-735.	2.8	49
17	Loss of heterozygosity on chromosome arm 3p in nasopharyngeal carcinoma. , 1996, 17, 118-126.		48
18	Mutation analysis of the CHK2 gene in breast carcinoma and other cancers. Breast Cancer Research, 2002, 4, R4.	5.0	46

#	Article	IF	Citations
19	Frequent occurrence of BRCA2 linkage in Icelandic breast cancer families and segregation of a common BRCA2 haplotype. American Journal of Human Genetics, 1996, 58, 749-56.	6.2	46
20	MicroRNA-451 suppresses tumor cell growth by down-regulating IL6R gene expression. Cancer Epidemiology, 2014, 38, 85-92.	1.9	45
21	High frequency of allelic imbalance at chromosome region 16q22-23 in human breast cancer: Correlation with high pgr and low s phase. International Journal of Cancer, 1995, 64, 112-116.	5.1	44
22	Duplicated Sequence Motif in the Long Terminal Repeat of Maedi-Visna Virus Extends Cell Tropism and Is Associated with Neurovirulence. Journal of Virology, 2007, 81, 4052-4057.	3.4	39
23	Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas. Cancer Research, 1999, 59, 2682-9.	0.9	39
24	Loss of heterozygosity on chromosome 9 in human breast cancer: Association with clinical variables and genetic changes at other chromosome regions. International Journal of Cancer, 1995, 64, 378-382.	5.1	36
25	Replication error in colorectal carcinoma: association with loss of heterozygosity at mismatch repair loci and clinicopathological variables. Anticancer Research, 1999, 19, 1821-6.	1.1	33
26	High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers. Oncogene, 1998, 16, 21-26.	5.9	31
27	Chromosome 8p alterations in sporadic and BRCA2 999del5 linked breast cancer. Journal of Medical Genetics, 2000, 37, 342-347.	3.2	31
28	Identification of a novel splice-site mutation of the BRCA1 gene in two breast cancer families: Screening reveals low frequency in Icelandic breast cancer patients. Human Mutation, 1998, 11, S195-S197.	2.5	30
29	Similar regions of human chromosome 3 are eliminated from or retained in human/human and human/mouse microcell hybrids during tumor growth in severe combined immunodeficient (SCID) mice. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 1136-1141.	7.1	29
30	Amplification of c-myc and pvt-1 homologous sequences in acute nonlymphatic leukemia. Leukemia Research, 1988, 12, 523-527.	0.8	26
31	A gene near the D3F15S2 site on 3p is expressed in normal human kidney but not or only at a severely reduced level in 11 of 15 primary renal cell carcinomas (RCC). Oncogene, 1990, 5, 1207-11.	5.9	26
32	Multiple chromosomal rearrangements in a spontaneously arising t(6;7) rat immunocytoma juxtapose c-myc and immunoglobulin heavy chain sequences Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 7376-7380.	7.1	25
33	Linkage analysis and allelic imbalance in human breast cancer kindreds using microsatellite markers from the short arm of chromosome 3. Human Genetics, 1995, 96, 437-43.	3.8	25
34	Quantitative Analysis of miRNA Expression in Seven Human Foetal and Adult Organs. PLoS ONE, 2011, 6, e28730.	2.5	25
35	Interstitial deletions including chromosome 3 common eliminated region 1 (C3CER1) prevail in human solid tumors from 10 different tissues. Genes Chromosomes and Cancer, 2004, 41, 232-242.	2.8	23
36	Similarities and differences in the regulation of N-myc and c-myc genes in murine embryonal carcinoma cells. Experimental Cell Research, 1987, 172, 304-317.	2.6	22

#	Article	IF	CITATIONS
37	Analysis of the fragile histidine triad (FHIT) gene in lobular breast cancer. European Journal of Cancer, 2000, 36, 1552-1557.	2.8	22
38	FHIT alterations in breast cancer. Seminars in Cancer Biology, 2001, 11, 361-366.	9.6	22
39	Quantitative analysis of miRNA expression in several developmental stages of human livers. Hepatology Research, 2010, 40, 813-822.	3.4	21
40	Specific polypeptide differences in normal versus malignant human breast tissues by two-dimensional electrophoresis. Breast Cancer Research and Treatment, 1987, 10, 177-189.	2.5	20
41	Structure and Expression of B- <i>myc</i> , a New Member of the <i>myc</i> Gene Family. Molecular and Cellular Biology, 1988, 8, 3168-3174.	2.3	20
42	Gene localization on sorted chromosomes: definitive evidence on the relative positioning of genes participating in the mouse plasmacytoma-associated typical translocation Proceedings of the National Academy of Sciences of the United States of America, 1985, 82, 6975-6979.	7.1	18
43	Loss of heterozygosity at chromosome 7q in human breast cancer: association with clinical variables. Anticancer Research, 1997, 17, 93-8.	1.1	18
44	Chromosome imbalance at the 3p14 region in human breast tumours: High frequency in patients with inherited predisposition due to BRCA2. European Journal of Cancer, 1998, 34, 142-147.	2.8	17
45	Isoenzyme pattern and subcellular localization of hexokinases in human breast cancer and nonpathological breast tissue. International Journal of Cancer, 1984, 34, 63-66.	5.1	16
46	The MLH1 â^'93 promoter variant influences gene expression. Cancer Epidemiology, 2010, 34, 93-95.	1.9	16
47	Drosophila homolog of the murine Int-1 protooncogene Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 3034-3038.	7.1	15
48	Identification of a breast tumor with microsatellite instability in a potential carrier of the hereditary nonâ€polyposis colon cancer trait. Clinical Genetics, 1995, 47, 305-310.	2.0	14
49	In vitro analysis of expression vectors for DNA vaccination of horses: the effect of a Kozak sequence. Acta Veterinaria Scandinavica, 2008, 50, 44.	1.6	14
50	Mapping ofLmyc andNmyc to rat chromosomes 5 and 6. Somatic Cell and Molecular Genetics, 1987, 13, 335-339.	0.7	13
51	Chromosome localization and expression pattern of Lmyc and Bmyc in murine embryonal carcinoma cells. Oncogene, 1988, 3, 679-85.	5.9	13
52	Nucleotide sequence of the rat Bmyc gene. Oncogene, 1989, 4, 1523-7.	5.9	13
53	Differences in C-myc andpvt-1 amplification in sewa sarcoma sublines selected for adherent or non-adherent growth. International Journal of Cancer, 1990, 45, 514-520.	5.1	12
54	Spreading of Alu Methylation to the Promoter of the MLH1 Gene in Gastrointestinal Cancer. PLoS ONE, 2011, 6, e25913.	2.5	12

#	Article	IF	CITATIONS
55	Identification of miRNAs in a Liver of a Human Fetus by a Modified Method. PLoS ONE, 2009, 4, e7594.	2.5	12
56	Chromosomal assignment of five cancer-associated rat genes: two thyroid hormone receptor (ERBA) genes, two ERBB genes and the retinoblastoma gene. Oncogene, 1991, 6, 1319-24.	5.9	12
57	High incidence of loss of heterozygosity in breast tumors from carriers of the BRCA2 999del5 mutation. Cancer Research, 1998, 58, 4421-5.	0.9	12
58	Ratc-raf oncogene is located on chromosome 4 and may be activated by sequences from chromosome 13. Somatic Cell and Molecular Genetics, 1988, 14, 401-405.	0.7	11
59	Replication error in human breast cancer: comparison with clinical variables and family history of cancer. Oncology Reports, 1999, 6, 117-22.	2.6	11
60	Loss of heterozygosity at the FHIT gene in different solid human tumours and its association with survival in colorectal cancer patients. Anticancer Research, 2002, 22, 3205-12.	1.1	11
61	Genetics of breast cancer. Drugs of Today, 2004, 40, 991.	2.4	9
62	High frequency of LOH at chromosome 18q in human breast cancer: association with high S-phase fraction and low progesterone receptor content. Anticancer Research, 1998, 18, 1031-6.	1.1	9
63	Population Studies and Validation of Paternity Determinations by Six Microsatellite Loci. Journal of Forensic Sciences, 2000, 45, 692-695.	1.6	8
64	Elevated expression of c-myc and N-myc produces distinct changes in nuclear fine structure and chromatin organization. Oncogene, 1988, 3, 587-93.	5.9	8
65	The rat MIS1/ <i>Pvt-1</i> locus is syntenic with MYC on chromosome 7. Cytogenetic and Genome Research, 1987, 45, 174-176.	1.1	4
66	The most frequently lost allelic site in human renal cell carcinoma (D3F15S2) on the short arm of chromosome 3 has homologous sequences on rat chromosome 8. Cytogenetic and Genome Research, 1991, 57, 149-150.	1.1	4
67	MAPPING OF CHROMOSOME-3 ALTERATIONS IN HUMAN BREAST-CANCER USING MICROSATELLITE PCR MARKERS - CORRELATION WITH CLINICAL-VARIABLES. International Journal of Oncology, 1995, 6, 369-75.	3.3	4
68	Demethylation of the region around exon 2 of MLH1 gene in gastrointestinal cancer. Anticancer Research, 2012, 32, 4861-4.	1.1	3
69	Urinary system tumours in a family. European Journal of Cancer, 1993, 29, 2335-2336.	2.8	2
70	Loss of heterozygosity at chromosome 1p in human breast cancer. International Journal of Oncology, 1996, 9, 731-6.	3.3	2
71	LOSS OF HETEROZYGOSITY AT CHROMOSOME 6Q CORRELATES WITH TUMOR PROGRESSION AND PATIENT SURVIVAL. International Journal of Oncology, 1995, 7, 871-6.	3.3	1
72	Altered expression of E-cadherin in breast cancer: patterns, mechanisms and clinical significance. European Journal of Cancer, 1999, 35, S90.	2.8	1

#	Article	lF	CITATIONS
73	Molecular Genetics of Breast Cancer. International Journal of Human Genetics, 2003, 3, 69-78.	0.1	1
74	The v-erbA Oncoprotein of the AEV Transforming Retrovirus Binds to the Promoter Region of the Erythroid-specific Band 3 Gene. Annals of the New York Academy of Sciences, 1994, 724, 426-429.	3.8	0
75	"Elimination test†Solid tumor progression model based on the nonrandom changes of human chromosome 3 in monochromosomal microcell hybrid. Cancer Genetics and Cytogenetics, 1996, 91, 185.	1.0	O
76	Deletions at the chromosome 3 common eliminated region 1 on 3p21.3 in human breast tumors. Breast Cancer Research, 2005, 7, 1.	5.0	0
77	Genomic Instability and Breast Cancer Progression. Cancer Genomics and Proteomics, 2006, 3, 137-146.	2.0	O
78	Tumor Suppressor Genes on Human Chromosome 3 and Cancer Pathogenesis. Cancer Genomics and Proteomics, 2005, 2, 247-253.	2.0	0